Your summary is correct. And the drug holiday question is important — it's something patients frequently ask about.

There is no clinical trial data supporting drug holidays for GLP-1 RAs. The STEP 1 extension data clearly showed that weight regain begins rapidly after discontinuation — most patients regained approximately two-thirds of lost weight within one year of stopping semaglutide[6].

Theoretically, a drug holiday might upregulate GLP-1R surface expression and restore some degree of receptor sensitivity. But the rapid weight regain during the holiday would likely negate any benefit. You'd lose weight, stop the drug, regain weight (and metabolically, regained weight is disproportionately fat rather than lean mass), restart the drug, and hopefully lose the regained weight — but you're now starting from a worse body composition.

The better approach, in my clinical experience, is combination therapy. If you've plateaued on semaglutide monotherapy, discussing the addition of a complementary mechanism (metformin, topiramate, or in the near future, cagrilintide or switching to tirzepatide) with your physician is more evidence-based than cycling off the drug.

I experienced something similar at month 8. What actually helped break my plateau was adding structured resistance training (3x/week with progressive overload). My weight stopped dropping but I lost another 4 inches off my waist. My endocrinologist said this was probably recomposition — losing fat and gaining muscle at roughly equal rates.

Not a scientific answer, but practically, I think the focus on scale weight as the sole metric is problematic. Body composition, functional capacity, and metabolic health markers may continue to improve even when scale weight plateaus.

That's an excellent practical point and it aligns with emerging data. Resistance training during GLP-1 RA therapy has been shown to mitigate lean mass loss and may improve body composition beyond what scale weight captures[7]. The combination of pharmacotherapy + structured exercise is almost certainly more effective than either alone for long-term outcomes.

To close the loop on the original question: the weight loss plateau is a normal physiological phenomenon, likely driven more by metabolic adaptation than receptor desensitization. It does not mean the drug has stopped working — discontinuation data proves the drug is still actively suppressing weight. The plateau simply represents a new equilibrium between the drug's anorexigenic/metabolic effects and the body's counter-regulatory homeostatic defense.